[Federal Register Volume 86, Number 30 (Wednesday, February 17, 2021)]
[Rules and Regulations]
[Pages 9862-9866]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-03179]


-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 180

[EPA-HQ-OPP-2019-0492; FRL-10018-86]


Fluxametamide; Pesticide Tolerances

AGENCY: Environmental Protection Agency (EPA).

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: This regulation establishes tolerances for residues of 
fluxametamide in or on tea, dried and tea, instant. Nissan Chemical 
Corporation requested these tolerances under the Federal Food, Drug, 
and Cosmetic Act (FFDCA).

DATES: This regulation is effective February 17, 2021. Objections and 
requests for hearings must be received on or before April 19, 2021, and 
must be filed in accordance with the instructions provided in 40 CFR 
part 178 (see also Unit I.C. of the SUPPLEMENTARY INFORMATION).

ADDRESSES: The docket for this action, identified by docket 
identification (ID) number EPA-HQ-OPP-2019-0492, is available at http://www.regulations.gov or at the Office of Pesticide Programs Regulatory 
Public Docket (OPP Docket) in the Environmental Protection Agency 
Docket Center (EPA/DC), West William Jefferson Clinton Bldg., Rm. 3334, 
1301 Constitution Ave. NW, Washington, DC 20460-0001. The Public 
Reading Room is open from 8:30 a.m. to 4:30 p.m., Monday through 
Friday, excluding legal holidays. The telephone number for the Public 
Reading Room is (202) 566-1744, and the telephone number for the OPP 
Docket is (703) 305-5805.
    Due to the public health concerns related to COVID-19, the EPA 
Docket Center (EPA/DC) and Reading Room is closed to visitors with 
limited exceptions. The staff continues to provide remote customer 
service via email, phone, and webform. For the latest status 
information on EPA/DC services and docket access, visit http://www.epa.gov/dockets.

FOR FURTHER INFORMATION CONTACT: Marietta Echeverria, Registration 
Division (7505P), Office of Pesticide Programs, Environmental 
Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460-
0001; main telephone number: (703) 305-7090; email address: 
RDFRNotices@epa.gov.

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this action apply to me?

    You may be potentially affected by this action if you are an 
agricultural producer, food manufacturer, or pesticide manufacturer. 
The following list of North American Industrial Classification System 
(NAICS) codes is not intended to be exhaustive, but rather provides a 
guide to help readers determine whether this document applies to them. 
Potentially affected entities may include:
     Crop production (NAICS code 111).
     Animal production (NAICS code 112).
     Food manufacturing (NAICS code 311).
     Pesticide manufacturing (NAICS code 32532).

B. How can I get electronic access to other related information?

    You may access a frequently updated electronic version of EPA's 
tolerance regulations at 40 CFR part 180 through the Government 
Publishing Office's e-CFR site at http://www.ecfr.gov/cgi-bin/text-idx?&c=ecfr&tpl=/ecfrbrowse/Title40/40tab_02.tpl.

C. How can I file an objection or hearing request?

    Under FFDCA section 408(g), 21 U.S.C. 346a, any person may file an 
objection to any aspect of this regulation and may also request a 
hearing on those objections. You must file your objection or request a 
hearing on this regulation in accordance with the instructions provided 
in 40 CFR part 178. To ensure proper receipt by EPA, you must identify 
docket ID number EPA-HQ-OPP-2019-0492 in the subject line on the first 
page of your submission. All objections and requests for a hearing must 
be in writing, and must be received by the Hearing Clerk on or before 
April 19, 2021. Addresses for mail and hand delivery of objections and 
hearing requests are provided in 40 CFR 178.25(b).
    In addition to filing an objection or hearing request with the 
Hearing Clerk as described in 40 CFR part 178, please submit a copy of 
the filing (excluding any Confidential Business Information (CBI)) for 
inclusion in the public docket. Information not marked confidential 
pursuant to 40 CFR part 2 may be disclosed publicly by EPA without 
prior notice. Submit the non-CBI copy of your objection or hearing 
request, identified by docket ID number EPA-HQ-OPP-2019-0492, by one of 
the following methods:
     Federal eRulemaking Portal: http://www.regulations.gov. 
Follow the online instructions for submitting comments. Do not submit 
electronically any information you consider to be CBI or other 
information whose disclosure is restricted by statute.

[[Page 9863]]

     Mail: OPP Docket, Environmental Protection Agency Docket 
Center (EPA/DC), (28221T), 1200 Pennsylvania Ave. NW, Washington, DC 
20460-0001.
     Hand Delivery: To make special arrangements for hand 
delivery or delivery of boxed information, please follow the 
instructions at http://www.epa.gov/dockets/contacts.html.
    Additional instructions on commenting or visiting the docket, along 
with more information about dockets generally, is available at http://www.epa.gov/dockets.

II. Summary of Petitioned-For Tolerance

    In the Federal Register of February 11, 2020 (85 FR 7708) (FRL-
10005-02), EPA issued a document pursuant to FFDCA section 408(d)(3), 
21 U.S.C. 346a(d)(3), announcing the filing of a pesticide petition (PP 
9E8757) by Nissan Chemical Corporation, 5-1, Nihonbashi 2-Chome Chuo-
Ku, Tokyo 101-6119 Japan, c/o Lewis and Harrison, 2461 South Clark 
Street, Suite 710, Arlington, VA 22202. The petition requested that 40 
CFR part 180 be amended by establishing tolerances for residues of the 
insecticide fluxametamide, including its metabolites and degradates, in 
or on tea at 5 parts per million (ppm). That document referenced a 
summary of the petition prepared by Nissan Chemical Corporation c/o 
Lewis and Harrison, the registrant, which is available in the docket, 
http://www.regulations.gov. There were no comments received in response 
to the notice of filing.
    Based upon review of the data supporting the petition, EPA has 
revised the commodity definition and is establishing a tolerance for 
tea, dried and tea, instant. The reasons for these changes are 
explained in Unit IV.C.

III. Aggregate Risk Assessment and Determination of Safety

    Section 408(b)(2)(A)(i) of FFDCA allows EPA to establish a 
tolerance (the legal limit for a pesticide chemical residue in or on a 
food) only if EPA determines that the tolerance is ``safe.'' Section 
408(b)(2)(A)(ii) of FFDCA defines ``safe'' to mean that ``there is a 
reasonable certainty that no harm will result from aggregate exposure 
to the pesticide chemical residue, including all anticipated dietary 
exposures and all other exposures for which there is reliable 
information.'' This includes exposure through drinking water and in 
residential settings, but does not include occupational exposure. 
Section 408(b)(2)(C) of FFDCA requires EPA to give special 
consideration to exposure of infants and children to the pesticide 
chemical residue in establishing a tolerance and to ``ensure that there 
is a reasonable certainty that no harm will result to infants and 
children from aggregate exposure to the pesticide chemical residue. . . 
.''
    Consistent with FFDCA section 408(b)(2)(D), and the factors 
specified in FFDCA section 408(b)(2)(D), EPA has reviewed the available 
scientific data and other relevant information in support of this 
action. EPA has sufficient data to assess the hazards of and to make a 
determination on aggregate exposure for fluxametamide including 
exposure resulting from the tolerances established by this action. 
EPA's assessment of exposures and risks associated with fluxametamide 
follows.

A. Toxicological Profile

    EPA has evaluated the available toxicity data and considered its 
validity, completeness, and reliability as well as the relationship of 
the results of the studies to human risk. EPA has also considered 
available information concerning the variability of the sensitivities 
of major identifiable subgroups of consumers, including infants and 
children.
    Fluxametamide belongs to a class of compounds called isoxazolines, 
which are potent inhibitors of [gamma]-aminobutyric acid (GABA)-, 
glutamate-, and glycine-gated chloride channels in insects. However, 
this pesticidal mode of action (MOA) does not seem to be operative in 
mammals as neurotoxicity was not found in either the acute or 
subchronic neurotoxicity studies at the limit dose.
    The available studies show different organs can be affected. For 
the dietary toxicity studies in rats (neurotoxicity study, chronic/
carcinogenicity, and reproductive toxicity studies), a common effect on 
the gastrointestinal (GI) tract was observed. The effects consisted of 
gross pathology (an increase incidence of abnormally pale color 
duodenum and jejunum) and histopathology (increased incidence of 
enterocyte epithelial vacuolation of the jejunum). Most of the effects 
seen in the subchronic neurotoxicity study were reproduced in the 
combined chronic and carcinogenicity study with increased severity and 
at lower dose level. In addition, consistent adverse effects were found 
in the lung (aggregate alveolar marcophages and cholesterol cleft) and 
liver (centrilobular hepatocellular vacuolation and periportal 
hepatocellular vacuolation). These adverse effects were present at a 
dose as low as 9 mg/kg/day in the carcinogenicity study.
    Fluxametamide is classified as having ``suggestive evidence of 
carcinogenic potential'' based on thyroid tumors in male rats and liver 
tumors in male mice. The reasons for this classification are (1) both 
tumor types are driven by adenomas, (2) these increased tumor 
incidences are seen at the highest doses tested (877 mg/kg/day for male 
mice and 899 mg/kg/day for male rats); these doses are approaching the 
limit dose (1000 mg/kg/day) for a carcinogenicity study, (3) there is 
no hyperplasia of the liver in either male or female mice, (4) no 
increase in treatment-related tumors has been observed in female mice 
or female rats, and (5) no genotoxicity is observed in the required 
battery of mutagenic studies. Due to the lack of genotoxicity and the 
fact that the tumors are seen only at doses more than 100-fold above 
the chronic reference dose, EPA has determined that a non-linear 
approach relying on the chronic reference dose (RfD) will adequately 
account for all chronic toxicity, including carcinogenicity, that could 
result from exposure to fluxametamide.
    The in-utero and perinatal treatment with fluxametamide in rats 
resulted in toxicity and increased quantitative susceptibility in 
developing animals. In the 2-generation reproduction study, 
fluxametamide produced no parental effect at the highest dose tested 
(19 mg/kg/day), while at the same dose level produced offspring effect 
which consisted of the observation that the pups had distended abdomens 
and affected pups had to be sacrificed for humane reason. The dermal 
toxicity study did not show systemic toxicity at the limit dose (1000 
mg/kg/day).
    Specific information on the studies received and the nature of the 
adverse effects caused by fluxametamide, as well as the no-observed-
adverse-effect-level (NOAEL) and the lowest-observed-adverse-effect-
level (LOAEL) from the toxicity studies, can be found at http:/
www.regulations.gov in document titled ``Fluxametamide: Human Health 
Risk Assessment to Support the Establishment of a Tolerance without 
U.S. Registration in/on Tea. First Food Use'' hereinafter 
``Fluxametamide Human Health Risk Assessment'' at pages 16-22 in docket 
ID number EPA-HQ-OPP-2019-0492.

B. Toxicological Points of Departure/Levels of Concern

    Once a pesticide's toxicological profile is determined, EPA 
identifies toxicological points of departure (POD) and levels of 
concern to use in evaluating the risk posed by human exposure to the 
pesticide. For hazards that have a threshold below which there is no 
appreciable risk, the toxicological POD is used as the basis for 
derivation

[[Page 9864]]

of reference values for risk assessment. PODs are developed based on a 
careful analysis of the doses in each toxicological study to determine 
the dose at which no adverse effects are observed (the NOAEL) and the 
lowest dose at which adverse effects of concern are identified (the 
LOAEL). Uncertainty/safety factors are used in conjunction with the POD 
to calculate a safe exposure level--generally referred to as a 
population-adjusted dose (PAD) or a reference dose (RfD)--and a safe 
margin of exposure (MOE). For non-threshold risks, the Agency assumes 
that any amount of exposure will lead to some degree of risk. Thus, the 
Agency estimates risk in terms of the probability of an occurrence of 
the adverse effect expected in a lifetime. For more information on the 
general principles EPA uses in risk characterization and a complete 
description of the risk assessment process, see http://www2.epa.gov/pesticide-science-and-assessing-pesticide-risks/assessing-human-health-risk-pesticide.
    A summary of the toxicological endpoints for fluxametamide used for 
human risk assessment can be found in the Fluxametamide Human Health 
Risk Assessment.

C. Exposure Assessment

    1. Dietary exposure from food and feed uses. In evaluating dietary 
exposure to fluxametamide, EPA considered exposure under the 
petitioned-for tolerances. EPA assessed dietary exposures from 
fluxametamide in food as follows:
    i. Acute exposure. Quantitative acute dietary exposure and risk 
assessments are performed for a food-use pesticide, if a toxicological 
study has indicated the possibility of an effect of concern occurring 
as a result of a 1-day or single exposure. No such effects were 
identified in the toxicological studies for fluxametamide; therefore, a 
quantitative acute dietary exposure assessment is unnecessary.
    ii. Chronic exposure. In conducting the chronic dietary exposure 
assessment EPA used 2003-2008 food consumption data from the United 
States Department of Agriculture's (USDA) National Health and Nutrition 
Examination Survey, What We Eat in America, (NHANES/WWEIA). As to 
residue levels in food, EPA assumed tolerance-level residues of 
fluxametamide on tea and 100% crop treated.
    iii. Cancer. EPA determines whether quantitative cancer exposure 
and risk assessments are appropriate for a food-use pesticide based on 
the weight of the evidence from cancer studies and other relevant data. 
Based on the data summarized in Unit III.A., EPA has concluded that a 
nonlinear RfD approach will adequately account for all chronic 
toxicity, including carcinogenicity, that could result from exposure to 
fluxametimide. A separate cancer dietary exposure and risk assessment 
is not required. Cancer risk was assessed using the same exposure 
estimates as discussed in Unit III.C.1.ii., chronic exposure.
    iv. Anticipated residue and percent crop treated (PCT) information. 
EPA did not use anticipated residue and/or PCT information in the 
dietary assessment for fluxametamide. Tolerance level residues and/or 
100 PCT were assumed for all food commodities.
    2. Dietary exposure from drinking water. EPA assumes that there is 
no exposure through drinking water because fluxametamide is not 
registered for use in the United States. Because residues are not 
expected in drinking water, dietary risk estimates include exposures 
from food only.
    3. From non-dietary exposure. The term ``residential exposure'' is 
used in this document to refer to non-occupational, non-dietary 
exposure (e.g., for lawn and garden pest control, indoor pest control, 
termiticides, and flea and tick control on pets). Fluxametamide is not 
being proposed to be registered for any specific use patterns that 
would result in residential exposure.
    4. Cumulative effects from substances with a common mechanism of 
toxicity. Section 408(b)(2)(D)(v) of FFDCA requires that, when 
considering whether to establish, modify, or revoke a tolerance, the 
Agency consider ``available information'' concerning the cumulative 
effects of a particular pesticide's residues and ``other substances 
that have a common mechanism of toxicity.''
    Unlike other pesticides for which EPA has followed a cumulative 
risk approach based on a common mechanism of toxicity, EPA has not made 
a common mechanism of toxicity finding as to fluxametamide and any 
other substances and fluxametamide does not appear to produce a toxic 
metabolite produced by other substances. For the purposes of this 
action, therefore, EPA has not assumed that fluxametamide has a common 
mechanism of toxicity with other substances.

D. Safety Factor for Infants and Children

    1. In general. Section 408(b)(2)(C) of FFDCA provides that EPA 
shall apply an additional tenfold (10X) margin of safety for infants 
and children in the case of threshold effects to account for prenatal 
and postnatal toxicity and the completeness of the database on toxicity 
and exposure unless EPA determines based on reliable data that a 
different margin of safety will be safe for infants and children. This 
additional margin of safety is commonly referred to as the FQPA Safety 
Factor (SF). In applying this provision, EPA either retains the default 
value of 10X, or uses a different additional safety factor when 
reliable data available to EPA support the choice of a different 
factor.
    2. Prenatal and postnatal sensitivity. There is an increase in 
quantitative susceptibility in two-generation reproductive toxicity 
study in rats. In this study, parental animals showed no adverse 
effects at 19 mg/kg/day (highest dose tested, HDT), whereas some pups 
had to be euthanized due to distended abdomen at the same dose. 
However, the concern is low because there was a clear NOAEL for the 
offspring effect (6 mg/kg/day) and the POD selected for chronic dietary 
exposure assessment (1 mg/kg/day) is protective of the offspring 
effects seen in the reproductive toxicity study.
    3. Conclusion. EPA has determined that reliable data show the 
safety of infants and children would be adequately protected if the 
FQPA SF were reduced to 1X. That decision is based on the following 
findings:
    i. The toxicity database for fluxametamide is complete.
    ii. There is no indication that fluxametamide is a neurotoxic 
chemical and there is no need for a developmental neurotoxicity study 
or additional UFs to account for neurotoxicity.
    iii. There is evidence of an increase in quantitative 
susceptibility in the 2-generation reproductive toxicity study in rats. 
In this study, parental animals showed no adverse effects at 19 mg/kg/
day highest dose tested, (HDT), whereas some pups had to be euthanized 
due to distended abdomen at the same dose. However, the concern is low 
because there was a clear NOAEL for the offspring effect (6 mg/kg/day) 
and the POD selected for chronic dietary exposure assessment (1 mg/kg/
day) is protective of the offspring effects seen in the reproductive 
toxicity study. The selected points of departure for risk assessment 
are protective of the quantitative increase in susceptibility seen in 
the rat reproductive toxicity study, for which a clear NOAEL and LOAEL 
are established.
    iv. There are no residual uncertainties identified in the exposure 
databases. The dietary food exposure assessments were performed based 
on 100 PCT and tolerance-level residues. These

[[Page 9865]]

assessments will not underestimate the exposure and risks posed by 
fluxametamide.

E. Aggregate Risks and Determination of Safety

    EPA determines whether acute and chronic dietary pesticide 
exposures are safe by comparing aggregate exposure estimates to the 
acute PAD (aPAD) and chronic PAD (cPAD). For linear cancer risks, EPA 
calculates the lifetime probability of acquiring cancer given the 
estimated aggregate exposure. Short-, intermediate-, and chronic-term 
risks are evaluated by comparing the estimated aggregate food, water, 
and residential exposure to the appropriate PODs to ensure that an 
adequate MOE exists.
    1. Acute risk. An acute aggregate risk assessment takes into 
account acute exposure estimates from dietary consumption of food and 
drinking water. No adverse effect resulting from a single oral exposure 
was identified and no acute dietary endpoint was selected. Therefore, 
fluxametamide is not expected to pose an acute risk.
    2. Chronic risk. Using the exposure assumptions described in this 
unit for chronic exposure, EPA has concluded that chronic exposure to 
fluxametamide from food only will utilize less than 1% of the cPAD for 
all population subgroups. There are no residential uses for 
fluxametamide.
    3. Short-and intermediate-term risk. Short- and intermediate-term 
aggregate exposure takes into account short- and intermediate-term 
residential exposure plus chronic exposure to food and water 
(considered to be a background exposure level). Because fluxametamide 
is not registered in the United States, the only exposures will be 
dietary, from residues in or on imported tea; therefore, no short-term 
or intermediate-term residential exposure is expected. Because there is 
no short- or intermediate-term residential exposure and chronic dietary 
exposure has already been assessed under the appropriately protective 
cPAD (which is at least as protective as the POD used to assess short-
term risk), no further assessment of short- or intermediate-term risk 
is necessary, and EPA relies on the chronic dietary risk assessment for 
evaluating short- and intermediate-term risk for fluxametamide.
    4. Aggregate cancer risk for U.S. population. As stated in Unit 
III.A., EPA has concluded that the chronic reference dose (RfD) will 
adequately account for all repeated exposure/chronic toxicity, 
including carcinogenicity, which could result from exposure to 
fluxametamide. Based on the lack of chronic risk at regulated levels of 
exposure, EPA concludes that exposure to fluxametamide will not pose an 
aggregate cancer risk.
    5. Determination of safety. Based on these risk assessments, EPA 
concludes that there is a reasonable certainty that no harm will result 
to the general population, or to infants and children from aggregate 
exposure to fluxametamide residues.

IV. Other Considerations

A. Analytical Enforcement Methodology

    Adequate enforcement methodology (high-performance liquid 
chromatography method with tandem mass spectrometry detection (LC/MS/
MS), Method NCI-2012-101/NCI-2013-017) is available to enforce the 
tolerance expression.
    The method may be requested from: Chief, Analytical Chemistry 
Branch, Environmental Science Center, 701 Mapes Rd., Ft. Meade, MD 
20755-5350; telephone number: (410) 305-2905; email address: 
residuemethods@epa.gov.

B. International Residue Limits

    In making its tolerance decisions, EPA seeks to harmonize U.S. 
tolerances with international standards whenever possible, consistent 
with U.S. food safety standards and agricultural practices. EPA 
considers the international maximum residue limits (MRLs) established 
by the Codex Alimentarius Commission (Codex), as required by FFDCA 
section 408(b)(4). The Codex Alimentarius is a joint United Nations 
Food and Agriculture Organization/World Health Organization food 
standards program, and it is recognized as an international food safety 
standards-setting organization in trade agreements to which the United 
States is a party. EPA may establish a tolerance that is different from 
a Codex MRL; however, FFDCA section 408(b)(4) requires that EPA explain 
the reasons for departing from the Codex level.
    The Codex has not established an MRL for fluxametamide.

C. Revisions to Petitioned-For Tolerances

    The petition requested a tolerance for residues of fluxametamide in 
or on tea. Since dried tea is the commodity that enters commerce, EPA 
is establishing the tolerance for the processed commodity tea, dried 
rather than tea, plucked leaves. EPA is also establishing a tolerance 
for tea, instant, which is another processed commodity of tea, plucked 
leaves, and EPA has determined that the same tolerance of 5 ppm is 
appropriate for instant tea.

V. Conclusion

    Therefore, tolerances are established for residues of 
fluxametamide, including its metabolites and degradates, in or on tea, 
dried at 5 ppm and tea, instant at 5 ppm.

VI. Statutory and Executive Order Reviews

    This action establishes tolerances under FFDCA section 408(d) in 
response to a petition submitted to the Agency. The Office of 
Management and Budget (OMB) has exempted these types of actions from 
review under Executive Order 12866, entitled ``Regulatory Planning and 
Review'' (58 FR 51735, October 4, 1993). Because this action has been 
exempted from review under Executive Order 12866, this action is not 
subject to Executive Order 13211, entitled ``Actions Concerning 
Regulations That Significantly Affect Energy Supply, Distribution, or 
Use'' (66 FR 28355, May 22, 2001) or Executive Order 13045, entitled 
``Protection of Children from Environmental Health Risks and Safety 
Risks'' (62 FR 19885, April 23, 1997), nor is it considered a 
regulatory action under Executive Order 13771, entitled ``Reducing 
Regulations and Controlling Regulatory Costs'' (82 FR 9339, February 3, 
2017). This action does not contain any information collections subject 
to OMB approval under the Paperwork Reduction Act (PRA) (44 U.S.C. 3501 
et seq.), nor does it require any special considerations under 
Executive Order 12898, entitled ``Federal Actions to Address 
Environmental Justice in Minority Populations and Low-Income 
Populations'' (59 FR 7629, February 16, 1994).
    Since tolerances and exemptions that are established on the basis 
of a petition under FFDCA section 408(d), such as the tolerances in 
this final rule, do not require the issuance of a proposed rule, the 
requirements of the Regulatory Flexibility Act (RFA) (5 U.S.C. 601 et 
seq.), do not apply.
    This action directly regulates growers, food processors, food 
handlers, and food retailers, not States or Tribes, nor does this 
action alter the relationships or distribution of power and 
responsibilities established by Congress in the preemption provisions 
of FFDCA section 408(n)(4). As such, the Agency has determined that 
this action will not have a substantial direct effect on States or 
Tribal Governments, on the relationship between the National Government 
and the States or Tribal Governments, or on the distribution of

[[Page 9866]]

power and responsibilities among the various levels of government or 
between the Federal Government and Indian Tribes. Thus, the Agency has 
determined that Executive Order 13132, entitled ``Federalism'' (64 FR 
43255, August 10, 1999) and Executive Order 13175, entitled 
``Consultation and Coordination with Indian Tribal Governments'' (65 FR 
67249, November 9, 2000) do not apply to this action. In addition, this 
action does not impose any enforceable duty or contain any unfunded 
mandate as described under Title II of the Unfunded Mandates Reform Act 
(UMRA) (2 U.S.C. 1501 et seq.).
    This action does not involve any technical standards that would 
require Agency consideration of voluntary consensus standards pursuant 
to section 12(d) of the National Technology Transfer and Advancement 
Act (NTTAA) (15 U.S.C. 272 note).

VII. Congressional Review Act

    Pursuant to the Congressional Review Act (5 U.S.C. 801 et seq.), 
EPA will submit a report containing this rule and other required 
information to the U.S. Senate, the U.S. House of Representatives, and 
the Comptroller General of the United States prior to publication of 
the rule in the Federal Register. This action is not a ``major rule'' 
as defined by 5 U.S.C. 804(2).

List of Subjects in 40 CFR Part 180

    Environmental protection, Administrative practice and procedure, 
Agricultural commodities, Pesticides and pests, Reporting and 
recordkeeping requirements.

    Dated: January 19, 2021.
Edward Messina,
Acting Director, Office of Pesticide Programs.

    Therefore, for the reasons stated in the preamble, EPA is amending 
40 CFR chapter I as follows:

PART 180--TOLERANCES AND EXEMPTIONS FOR PESTICIDE CHEMICAL RESIDUES 
IN FOOD

0
1. The authority citation for part 180 continues to read as follows:


    Authority:  21 U.S.C. 321(q), 346a and 371.

0
2. Add Sec.  180.715 to subpart C to read as follows:


Sec.  180.715  Fluxametamide; tolerances for residues.

    (a) General. Tolerances are established for residues of the 
insecticide fluxametamide, including its metabolites and degradates, in 
or on the commodities to Table 1 of this section. Compliance with the 
tolerance levels specified in Table 1 is to be determined by measuring 
only residues of fluxametamide, 4-[5-(3,5-dichlorophenyl)-4,5-dihydro-
5-(trifluoromethyl)-3-isoxazolyl]-N-[(methoxyamino)methylene]-2-
methylbenzamide in or on the commodities:

                        Table 1 to Paragraph (a)
------------------------------------------------------------------------
                                                             Parts per
                        Commodity                             million
------------------------------------------------------------------------
Tea, dried..............................................               5
Tea, instant............................................               5
------------------------------------------------------------------------

    (b)-(d) [Reserved]

[FR Doc. 2021-03179 Filed 2-16-21; 8:45 am]
BILLING CODE 6560-50-P


